A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2016
At a glance
- Drugs Aripiprazole lauroxil (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Alkermes
- 13 Jul 2016 Status changed from active, no longer recruiting to completed.
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.
- 24 Dec 2015 New trial record